New Sites Open for Roche's Phase 2/3 Study of RG6206

PMIdLs6J.jpeg

The following sites Roche's Phase 2/3 Study of RG6206 have opened for enrollment.

Additional information about this study, titled, Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular Dystrophy, can be found here